Physician profile
Ali Ghorbani
NPI 1932192291
$1,805.98
in general payments reported to CMS, 2019-2025
18 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2021: $314 · 2022: $425 · 2023: $420 · 2024: $185 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.93 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $394.37 | 2019-2025 | Velphoro, Velphoro |
| Stryker Corporation | $274.08 | 2022 | |
| Vifor Pharma, INC. | $261.69 | 2021-2025 | Veltassa |
| Amgen INC. | $233.32 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals Lp | $141.89 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $101.53 | 2022-2025 | |
| Travere Therapeutics, INC. | $57.38 | 2023 | |
| Novartis Pharmaceuticals Corporation | $53.24 | 2024 | |
| Medtronic Vascular, INC. | $51.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $48.44 | 2019-2023 | Jynarque |
| Ardelyx, INC. | $33.41 | 2025 | Ibsrela |
| Boston Scientific Corporation | $31.58 | 2024 | Eluvia, Wavewriter Alpha Prime 16 |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $22.39 | 2023 | Alunbrig |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.10 | 2025 | |
| Biolase, INC. | $19.09 | 2019 | |
| Biohorizons Implant Systems INC. | $18.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Ghorbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.